- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04580771
A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial
IMMUNOCERV: Evaluating the Safety of Chemoradiation Combined With PDS0101 Immunotherapy in Treating Locally Advanced Cervical Cancer
Study Overview
Status
Conditions
- Locally Advanced Cervical Squamous Cell Carcinoma, Not Otherwise Specified
- Stage IB3 Cervical Cancer FIGO 2018
- Stage II Cervical Cancer FIGO 2018
- Stage IIA Cervical Cancer FIGO 2018
- Stage IIA1 Cervical Cancer FIGO 2018
- Stage IIA2 Cervical Cancer FIGO 2018
- Stage IIB Cervical Cancer FIGO 2018
- Stage III Cervical Cancer FIGO 2018
- Stage IIIA Cervical Cancer FIGO 2018
- Stage IIIB Cervical Cancer FIGO 2018
- Stage IIIC Cervical Cancer FIGO 2018
- Stage IIIC1 Cervical Cancer FIGO 2018
- Stage IIIC2 Cervical Cancer FIGO 2018
- Stage IVA Cervical Cancer FIGO 2018
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. Evaluate the safety and toxicity profile of delivering the immune nanoparticle liposomal HPV-16 E6/E7 multipeptide vaccine PDS0101 (PDS0101) with standard-of-care chemoradiation (chemoRT) in patients with locally advanced cervical cancer.
SECONDARY OBJECTIVES:
I. Rate of complete metabolic response on day 170 (+/- 14 days) positron emission tomography computed tomography (PET CT).
II. Rate of >= 90% gross tumor volume reduction day 35 magnetic resonance imaging (MRI) (+/- 5 days).
III. Report rates of local control (LC), progression-free survival (PFS), and overall survival (OS) at 12 and 18 months following chemoRT completion.
IV. Long-term safety: rate of grade >= 3 chronic toxicity (from day 81 to completion of trial).
EXPLORATORY HPV-SPECIFIC IMMUNE RESPONSE OBJECTIVES:
I. Enzyme-linked immunosorbent spot (ELISpot) assays on interferon-gamma and granzyme B levels in E6/7-specific T cells isolated from peripheral blood mononuclear cells (PBMCs).
II. Compare intratumoral T-cell receptor (TCR) clonality at baseline and end of treatment by TCR sequencing.
III. Measure CD4+ and CD8+ tumor-infiltrating lymphocytes (TILs) from cervical brush samples by using markers of T-cell exhaustion (PD1, CTLA4) and T cell-activation (granzyme B, CD69+).
IV. Assess the intestinal and cervical microbiome by analyzing rectal and cervical swab samples with 16s ribosomal ribonucleic acid (rRNA) sequencing.
V. Additional assays such as circulating tumor cells, circulating cell-free tumor deoxyribonucleic acid (DNA) (ccfDNA), and other assays will be performed at the discretion of the principal investigator.
OUTLINE:
Patients undergo radiation therapy over 1 hour 5 days per week (Monday-Friday) for 5-7 weeks and receive cisplatin intravenously (IV) over 4 hours once per week (QW) during the 5 weeks of radiation therapy in the absence of disease progression and unacceptable toxicity. Patients also receive PDS0101 subcutaneously (SC) on days -10, 7, 28, 49, and 170 in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days, 1, 4, 6, 12, and 18 weeks, and 18 months.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Ann H. Klopp
- Phone Number: 713-563-2444
- Email: aklopp@mdanderson.org
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- M D Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria
- Age 18 years or older
- Newly diagnosed locally advanced squamous cell carcinoma of cervix (FIGO 2018 stage IB3-IVA with primary tumor ≥ 5 cm and/or positive pelvic or periaortic nodal disease assessed by imaging).
- Histologic diagnosis of squamous cell carcinoma of the cervix.
- Written informed consent before initiation of any study-related procedures;
- WHO/ECOG performance status 0-2.
- Adequate liver (ALT, AST, Alk Phos and total Bili ≤ 2-fold the upper limit of normal), and renal functions (Creatinine ≤ 1.5).
- Absence of current malignancies at other sites, except for adequately treated basal or squamous cell carcinoma of the skin. Cancer survivors who have undergone potentially curative therapy for a prior malignancy who have no evidence of that disease for 5 years and who are deemed at low risk for recurrence are eligible for the study
Exclusion Criteria:
- HIV infection, cellular immune deficiencies, hypogammaglobulinemia or dysgammaglobulinemia, or hereditary or congenital immunodeficiencies
- Prior diagnosis of hepatitis B or C (unless anti-hepatitis C therapy has produced a sustained virologic response);
- History of clinically significant autoimmune disease, Crohn's disease, or ulcerative colitis
- Serious concomitant disorder, including active systemic infection requiring treatment, as judged by the Investigator.
- Receipt of immunotherapy (e.g., IFNs, check-point inhibitors, tumor necrosis factor, interleukins, etc.) or biological response modifiers (GM-CSF, granulocyte colony-stimulating factor, macrophage colony-stimulating factor) within 4 weeks before the first study vaccination.
Receipt of chronic systemic steroid therapy (in dosing exceeding 10mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.
• Current or recent use of physiologic doses of intra-articular, topical, or inhaled corticosteroids is acceptable.
- History of previous therapeutic HPV vaccination (individuals who have been immunized with licensed prophylactic HPV vaccines [e.g., Silgard®, Cervarix®, Gardasil®] are not excluded)
- Known or suspected hypersensitivity to any component of the investigational product or contraindications to cisplatin (e.g., peripheral neuropathy grade ≤ 2 or ototoxicity ≤grade 2 per CTCAE v5.0)
- Previous pelvic RT.
- Previous chemotherapy for the cervix tumor
- Previous hysterectomy or will have a hysterectomy as part of their initial cervical cancer therapy
- Prior major surgery within 4 weeks of enrollment from which the patient has not recovered
- Other condition or prior therapy that, in the opinion of the Investigator, compromises the subject's welfare or may confound study results
- Concurrent participation in another therapeutic investigational study or use of another investigational drug within 6 months before the first study vaccination
- Previous enrollment in this study
- HPV genotyping is to be done from cervical swab samples. Enrollment will not require HPV testing.
- Pregnancy: a female subject defined as a WOCBP who has a positive urine pregnancy test (e.g. within 72 hours) prior to treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (radiation therapy, cisplatin, PDS0101)
Patients undergo radiation therapy over 1 hour 5 days per week (Monday-Friday) for 5-7 weeks and receive cisplatin IV over 4 hours QW during the 5 weeks of radiation therapy in the absence of disease progression and unacceptable toxicity.
Patients also receive PDS0101 SC on days -10, 7, 28, 49, and 170 in the absence of disease progression or unacceptable toxicity.
|
Given IV
Other Names:
Undergo radiation therapy
Other Names:
Given SC
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of grade >= 3 acute toxicity
Time Frame: Day -10 to day 80
|
Measured from first vaccine injection up to 30 days following completion of chemoradiotherapy (chemoRT).
Adverse events (AEs) will be assessed using the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.
Any AE that occurs between the first day of PDS0101 injection and up to 30 days following completion of chemoRT (~Day 80) will be considered as acute toxicity (AT).
|
Day -10 to day 80
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of complete metabolic response
Time Frame: Day 170
|
Measured by positron emission tomography computed tomography (PET CT).
|
Day 170
|
Rate of >= 90% gross tumor volume reduction
Time Frame: Day 35
|
Measured by magnetic resonance imaging (MRI).
|
Day 35
|
Rates of local control
Time Frame: At 12 and 18 months
|
Will be represented by Kaplan-Meier curves.
|
At 12 and 18 months
|
Rates of progression-free survival
Time Frame: At 12 and 18 months
|
Will be represented by Kaplan-Meier curves.
|
At 12 and 18 months
|
Rates of overall survival
Time Frame: At 12 and 18 months
|
Will be represented by Kaplan-Meier curves.
|
At 12 and 18 months
|
Rate of grade >= 3 chronic toxicity
Time Frame: Day 81 to completion of trial
|
AEs will be assessed using the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.
Chronic toxicity (CT) is any toxicity that occurs outside of the AT window (between Days 81 and study completion of the study).
|
Day 81 to completion of trial
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ann H Klopp, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Cervical Diseases
- Uterine Diseases
- Neoplasms, Squamous Cell
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Uterine Cervical Neoplasms
- Carcinoma, Squamous Cell
- Physiological Effects of Drugs
- Antineoplastic Agents
- Immunologic Factors
- Cisplatin
- Vaccines
Other Study ID Numbers
- 2019-1260 (Other Identifier: M D Anderson Cancer Center)
- NCI-2020-06810 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Locally Advanced Cervical Squamous Cell Carcinoma, Not Otherwise Specified
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedCervical Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical CarcinomaUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI); Advaxis, Inc.CompletedCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical CarcinomaUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical Carcinoma | Persistent DiseaseUnited States
-
National Cancer Institute (NCI)NRG OncologyCompletedCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical Carcinoma | Stage IVB Cervical Cancer AJCC v6 and v7United States
-
GOG FoundationNational Cancer Institute (NCI)Active, not recruitingCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Stage IIA Cervical Cancer AJCC v7 | Stage IB Cervical Cancer AJCC v6 and v7 | Stage I Cervical Cancer AJCC v6 and v7 | Stage IA Cervical Cancer AJCC v6 and v7United States, Korea, Republic of, Japan
-
National Cancer Institute (NCI)Radiation Therapy Oncology GroupCompletedCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Stage IIA Cervical Cancer AJCC v7 | Stage IIB Cervical Cancer AJCC v6 and v7 | Stage III Cervical Cancer AJCC v6 and v7 | Stage IB Cervical Cancer AJCC v6 and v7United States, Canada
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Stage IA2 Cervical Cancer AJCC v6 and v7 | Stage IB1 Cervical Cancer AJCC v6 and v7United States, Brazil, Colombia, Peru, Mexico, Argentina, Australia, Thailand
-
National Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Stage IVA Cervical Cancer AJCC v6 and v7 | Recurrent Cervical Carcinoma | Stage IV Cervical Cancer AJCC v6 and v7 | Stage IVB Cervical Cancer AJCC v6 and v7United States
-
GOG FoundationNational Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Stage IIA Cervical Cancer AJCC v7 | Stage IIB Cervical Cancer AJCC v6 and v7 | Stage IIIB Cervical Cancer AJCC v6 and v7 | Stage IVA Cervical Cancer AJCC v6 and v7 | Stage IB Cervical...United States, Canada, Saudi Arabia, China, Singapore
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedVaginal Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical Carcinoma | Advanced Cervical Adenocarcinoma | Human Papillomavirus-Related Cervical Squamous Cell Carcinoma | Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma | Stage III Cervical Cancer AJCC v8 | Stage IIIA... and other conditionsUnited States
Clinical Trials on Cisplatin
-
West China Second University HospitalRecruitingNeoadjuvant Chemotherapy | Epithelial Carcinoma, OvarianChina
-
Insmed IncorporatedCompletedOsteosarcoma MetastaticUnited States
-
Privo TechnologiesNational Cancer Institute (NCI)CompletedOral Squamous Cell CarcinomaUnited States
-
Samsung Medical CenterUnknownNasophayngeal Carcinoma Between Stage II and IVbKorea, Republic of
-
Cedars-Sinai Medical CenterRecruitingHPV Positive Oropharyngeal Squamous Cell CarcinomaUnited States
-
Korea Cancer Center HospitalCompletedCervical CancersKorea, Republic of
-
Taiho Oncology, Inc.Quintiles, Inc.Completed
-
Lawson Health Research InstituteRecruitingLocally Advanced Head and Neck Squamous Cell CarcinomaCanada
-
Sun Yat-sen UniversityActive, not recruitingNasopharyngeal CarcinomaChina
-
Sun Yat-sen UniversityFirst Affiliated Hospital, Sun Yat-Sen University; Guangdong Provincial People... and other collaboratorsActive, not recruitingNasopharyngeal Carcinoma | Nasopharyngeal Neoplasms | Nasopharyngeal Diseases | Head and Neck NeoplasmChina